November 10, 2006 -- Catalyst Pharmaceutical Partners priced its IPO at $6 per share earlier this week, cutting the price in half from the expected range of $11-$13. Catalyst is a very young, very early-stage company. It has one drug candidate that aims to help addicts kick their cocaine habits. But the drug has yet to enter a Phase II trial in the US, though Catalyst put CPP-109 through a small Phase II trial in Mexico. We look at the single drug in development for Catalyst and its prospects...
